Chronic Myelogenous Leukemia, Version 1.2014 Featured Updates to the NCCN Guidelines

被引：47

作者：

O'Brien, Susan ^{[1
]}

Radich, Jerald P. ^{[2
]}

Abboud, Camille N. ^{[3
]}

Akhtari, Mojtaba

Altman, Jessica K. ^{[4
]}

Berman, Ellin ^{[5
]}

DeAngelo, Daniel J. ^{[6
]}

Deininger, Michael ^{[7
]}

Devine, Steven ^{[8
]}

Fathi, Amir T. ^{[9
]}

Gotlib, Jason ^{[10
]}

Jagasia, Madan ^{[11
]}

Kropf, Patricia ^{[12
]}

Moore, Joseph O.

Pallera, Arnel ^{[13
]}

Pinilla-Ibarz, Javier ^{[14
]}

Reddy, Vishnu Vb. ^{[15
]}

Shah, Neil P.

Smith, B. Douglas

Snyder, David S.

Wetzler, Meir ^{[16
]}

Gregory, Kristina

Sundar, Hema

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[3] Washington Univ, Sch Med, St Louis, MO 63130 USA

[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[6] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[8] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA

[9] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[10] Stanford Canc Inst, Stanford, CA USA

[11] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[12] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

[13] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[15] Univ Alabama, Birmingham Comprehens Canc Ctr, Tuscaloosa, AL 35487 USA

[16] Roswell Pk Canc Inst, Buffalo, NY USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2013年 / 11卷 / 11期

关键词：

CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; HARMONIZING CURRENT METHODOLOGY; BCR-ABL1 TRANSCRIPT LEVELS; ALPHA PLUS CYTARABINE; BCR-ABL TRANSCRIPTS; DASATINIB; 100; MG; CHRONIC-PHASE; MOLECULAR RESPONSES; INTOLERANT PATIENTS;

D O I：

10.6004/jnccn.2013.0157

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level <= 10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).

引用

页码：1327 / 1340

页数：14

共 48 条

[1] Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program [J].

Beillard, E ;

Pallisgaard, N ;

van der Velden, VHJ ;

Bi, W ;

Dee, R ;

van der Schoot, E ;

Delabesse, E ;

Macintyre, E ;

Gottardi, E ;

Saglio, G ;

Watzinger, F ;

Lion, T ;

van Dongen, JJM ;

Hokland, P ;

Gabert, J .

LEUKEMIA, 2003, 17 (12) :2474-2486

[2] Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia [J].

Branford, S. ;

Cross, N. C. P. ;

Hochhaus, A. ;

Radich, J. ;

Saglio, G. ;

Kaeda, J. ;

Goldman, J. ;

Hughes, T. .

LEUKEMIA, 2006, 20 (11) :1925-1930

[3] Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations [J].

Branford, S ;

Rudzki, Z ;

Parkinson, I ;

Grigg, A ;

Taylor, K ;

Seymour, JF ;

Durrant, S ;

Browett, P ;

Schwarer, AP ;

Arthur, C ;

Catalano, J ;

Leahy, MF ;

Filshie, R ;

Bradstock, K ;

Herrmann, R ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2004, 104 (09) :2926-2932

[4] Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase [J].

Branford, S ;

Rudzki, Z ;

Harper, A ;

Grigg, A ;

Taylor, K ;

Durrant, S ;

Arthur, C ;

Browett, P ;

Schwarer, AP ;

Ma, D ;

Seymour, JF ;

Bradstock, K ;

Joske, D ;

Lynch, K ;

Gathmann, I ;

Hughes, TP .

LEUKEMIA, 2003, 17 (12) :2401-2409

[5] Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials [J].

Branford, Susan ;

Fletcher, Linda ;

Cross, Nicholas C. P. ;

Mueller, Martin C. ;

Hochhaus, Andreas ;

Kim, Dong-Wook ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Pane, Fabrizio ;

Kamel-Reid, Suzanne ;

Wang, Y. Lynn ;

Press, Richard D. ;

Lynch, Kevin ;

Rudzki, Zbigniew ;

Goldman, John M. ;

Hughes, Timothy .

BLOOD, 2008, 112 (08) :3330-3338

[6] Initial Molecular Response at 3 Months May Predict Both Response and Event-Free Survival at 24 Months in Imatinib-Resistant or -Intolerant Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated With Nilotinib [J].

Branford, Susan ;

Kim, Dong-Wook ;

Soverini, Simona ;

Haque, Ariful ;

Shou, Yaping ;

Woodman, Richard C. ;

Kantarjian, Hagop M. ;

Martinelli, Giovanni ;

Radich, Jerald P. ;

Saglio, Giuseppe ;

Hochhaus, Andreas ;

Hughes, Timothy P. ;

Mueller, Martin C. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (35) :4323-4329

[7] Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate [J].

Cortes, J ;

Talpaz, M ;

O'Brien, S ;

Jones, D ;

Luthra, R ;

Shan, J ;

Giles, F ;

Faderl, S ;

Verstovsek, S ;

Garcia-Manero, G ;

Rios, MB ;

Kantarjian, H .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3425-3432

[8]

Cortes J, 2009, BLOOD, V114, P267

[9] A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Pinilla-Ibarz, Javier ;

le Coutre, Philipp ;

Paquette, Ron ;

Chuah, Charles ;

Nicolini, Franck E. ;

Apperley, Jane ;

Khoury, H. Jean ;

Talpaz, Moshe ;

DiPersio, John F. ;

DeAngelo, Daniel J. ;

Abruzzese, Elisabetta ;

Rea, Delphine ;

Baccarani, Michele ;

Muller, Martin C. ;

Gambacorti-Passerini, Carlo ;

Wong, Stephane ;

Lustgarten, Stephanie ;

Rivera, Victor M. ;

Clarkson, Tim ;

Turner, Christopher D. ;

Haluska, Frank G. ;

Guilhot, Francois ;

Deininger, Michael W. ;

Hochhaus, Andreas ;

Hughes, Timothy ;

Goldman, John M. ;

Shah, Neil ;

Kantarjian, Hagop M. .

BLOOD, 2012, 120 (21)

[10] Standardisation of molecular monitoring for chronic myeloid leukaemia [J].

Cross, Nicholas C. P. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2009, 22 (03) :355-365

← 1 2 3 4 5 →